Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
Anime Tokyo Station: TV Anime “SPY x FAMILY” Special Exhibition, Period: August 16 – November 9, 2025
Fujitsu, 1Finity and Arrcus sign strategic partnership agreement to deliver innovative network solutions for AI infrastructure
Hitachi has been certified as a Gold Partner of Scaled Agile, Inc., the provider of the large-scale agile framework “SAFe(R)”
Honda to Provide Official Vehicles for World Athletics Championships Tokyo 25 as Official Global Partner
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen) – Applications for Research Projects Open on September 1
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
The University of Tokyo and DENSO Jointly Establish a Social Cooperation Program: “Building Sustainable Production System Infrastructure with Advanced AI Technology”
